Trial Profile

A Multi-Center Pilot/Phase I and Phase II Clinical Trial of NG101m Adjuvant Therapy in Newly Diagnosed Glioblastoma Patients

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NG 101m (Primary) ; Temozolomide
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use
Sponsors NeuGATE Theranostics

Most Recent Events

13 Apr 2023 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.
13 Apr 2023 Planned primary completion date changed from 30 Jul 2026 to 30 Jul 2027.
13 Apr 2023 Planned initiation date changed from 1 Jan 2023 to 1 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com